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Abstract 49 
Granulocyte-macrophage colony stimulating factor (GM-CSF) induces production of 50 
granulocyte and macrophage populations from the hematopoietic progenitor cells; it is 51 
one of the most common growth factors in the blood. GM-CSF is also involved in 52 
bone cancer pain development by regulating tumor-nerve interactions, remodeling of 53 
peripheral nerves and sensitization of damage-sensing (nociceptive) nerves. However, 54 
the precise mechanism for GM-CSF-dependent pain is unclear. In this study, we found 55 
that GM-CSF is highly expressed in human malignant osteosarcoma. Female 56 
Sprague-Dawley rats implanted with bone cancer cells develop mechanical and 57 
thermal hyperalgesia but antagonizing GM-CSF in these animals significantly 58 
reduced such hypersensitivity. The voltage gated Na+ channels Nav1.7, Nav1.8 and 59 
Nav1.9 were found to be selectively up-regulated in rat DRG neurons treated with 60 
GM-CSF, which resulted in enhanced excitability. GM-CSF activated the Jak2 and 61 
Stat3 signaling pathway which promoted the transcription of Nav1.7-1.9 in DRG 62 
neurons. Accordingly, targeted knocking down of either Nav1.7-1.9 or Jak2/Stat3 in 63 
DRG neurons in vivo alleviated the hyperalgesia in male Sprague-Dawley rats. Our 64 
findings describe a novel bone cancer pain mechanism and provide a new insight into 65 
the physiological and pathological functions of GM-CSF. 66 
 67 
 68 
Significance Statement  69 
It has been reported that GM-CSF plays a key role in bone cancer pain, yet the 70 
underlying mechanisms involved in GM-CSF-mediated signaling pathway in 71 
nociceptors is not fully understood. Here, we showed that GM-CSF promotes bone 72 
cancer-associated pain by enhancing excitability of DRG neurons via the 73 
Jak2-Stat3-mediated upregulation of expression of nociceptor-specific voltage-gated 74 
sodium channels. Our study provides a detailed understanding of the roles that sodium 75 
channels and Jak2/Stat3 pathway play in the GM-CSF-mediated bone cancer pain; our 76 
data also highlight the therapeutic potential of targeting GM-CSF. 77 
  4 
Introduction 78 
Granulocyte-macrophage colony stimulating factor (GM-CSF) was originally 79 
identified as a colony stimulating factor because of its ability to induce granulocyte 80 
and macrophage populations from precursor cells. GM-CSF is also abundantly 81 
secreted by some tumor cells and plays a key role in regulating tumor-nerve 82 
interactions, remodeling of peripheral nerves and sensitization of damage-sensing 83 
nerves (nociceptors) by acting at its receptors (Schweizerhof et al., 2009). Apart of the 84 
bone metastases pain, GM±CSF was also shown to be involved in inflammatory pain, 85 
arthritic and neuropathic pains (Cook et al., 2012; Cook et al., 2013; Nicol et al., 86 
2018). A recent study show that GM-CSF signaling contributes to pain-associated 87 
behavior that is independent of a gliosis and/or astrocyte response, suggesting that 88 
GM-CSF may directly activate sensory neurons (Nicol et al., 2018). However, the 89 
precise mechanism for GM-CSF-dependent pain is unclear.  90 
Dorsal root ganglion (DRG) neurons are the peripheral somatic and visceral 91 
sensory neurons; a subset of these neurons is responsible for nociceptive signal 92 
initiation and propagation. Receptors for GM-CSF (GM-CSFR) are found to be 93 
expressed in DRG and in peripheral nerves dispersed in the periosteum of mice 94 
(Schweizerhof et al., 2009). Signaling cascades and mechanisms of action of 95 
GM-CSFR in sensory neurons are largely unknown but in hematopoietic cells, 96 
activation of GM-CSFR is known to stimulate cell signaling pathways regulating gene 97 
expression, including the Jak-Stat pathway (Janus kinase, JAK; signal transducer and 98 
activator of transcription protein, Stat) (Stosser et al., 2011). Activation of Jak leads to 99 
dimerization and translocation of Stat family transcription factors to cell nucleus to 100 
regulate gene expression (Fortin et al., 2007). The main aim of the present study was 101 
to identify molecules involved in GM-CSF-mediated signaling pathway in 102 
nociceptors and test their relevance to GM-CSF-induced pain.  103 
Ion channels are the basis of sensory neuronal excitability and were previously 104 
suggested as molecular targets of GM-CSF signaling pathway (Bali et al., 2013). Our 105 
preliminary screening (see Results and Figure 3-1) revealed that GM-CSF selectively 106 
increased expression in DRG neurons of three voltage-gated sodium channels, Nav1.7, 107 
  5 
Nav1.8 and Nav1.9. Due to the primary role of these channels in the ability of DRG 108 
neurons to generate action potentials (APs), we hypothesized that GM-CSF might 109 
promote pain and hyperalgesia by acting on voltage-gated Na+ channels in 110 
nociceptors.  111 
At least five different voltage-gated sodium channels are reportedly expressed in 112 
DRG, including the TTX-sensitive Nav1.1, Nav1.6 and Nav1.7 and the TTX-resistant 113 
Nav1.8 and Nav1.9 (Cummins et al., 2000). Nav1.7, Nav1.8 and Nav1.9 channels are 114 
mainly distributed in small diameter DRG neurons, most of which are involved in 115 
nociception. Nav1.7 produces a rapidly-activating and inactivating but slowly 116 
repriming current. It produces a robust ramp current in response to depolarizations, 117 
contributing to the generation and propagation of action potentials and acting as a 118 
threshold channel regulating excitability (Francois-Moutal et al., 2018; Li et al., 2018). 119 
Gain-of-function mutations within the Nav1.7 gene SCN9A lead to inherited pain 120 
disorders, such as erythromelalgia (IEM) and paroxysmal extreme pain disorder 121 
(PEPD) (Dib-Hajj et al., 2008; Jarecki et al., 2010; Cheng et al., 2011). Nav1.8 122 
mediates a slowly-inactivating sodium currents acting as a key component of the 123 
upstroke of the action potential and thus influences neuronal excitability and 124 
nociceptive transmission. Mutations of Nav1.8 gene, SCN10A, is found in patients 125 
with peripheral neuropathy (Lai et al., 2002; Choi et al., 2007; Blanchard et al., 2012). 126 
The Nav1.9 channel has a slow kinetics and is responsible for persistent Na+ currents 127 
in nociceptors; together with the Nav1.7 it acts as a threshold channel for AP firing; it 128 
amplifies sub-threshold stimuli leading to AP bursts (Huang et al., 2014). 129 
Gain-of-function mutations of Nav1.9 channel gene, SCN11A cause familial episodic 130 
pain syndrome (Huang et al., 2014; Huang et al., 2017).  131 
In this study, we found that GM-CSF significantly increased the excitability of 132 
DRG neurons in parallel with the increase the current density, mRNA and protein 133 
expression of Nav1.7, Nav1.8 and Nav1.9 channels. We further show 134 
Jak2-Stat3-mediated up-regulation of Nav1.7, Nav1.8 and Nav1.9 channel expression 135 
in nociceptors is a major factor in the GM-CSF-related component of bone cancer 136 
pain. 137 
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 138 
Materials and methods 139 
Human subjects. The study was carried out in accordance with the ethical 140 
principles for medical research involving human subjects set out in the Helsinki 141 
Declaration, and was approved by the ethical committee at Hebei Medical University 142 
(Shijiazhuang, China). Osteosarcoma or chondroma tissues were obtained from 8 143 
patients from the Fourth Hospital of Hebei Medical University. Each specimen was 144 
fixed with 4% paraformaldehyde for immunohistochemistry study. All patients or 145 
their relatives gave informed consent prior to their participation in the study.  146 
 147 
Animals. The animal protocols used in this study were approved by the Animal 148 
Care and Ethical Committee of Hebei Medical University under the International 149 
Association for the Study of Pain (IASP) guidelines for animal use. All surgeries were 150 
performed under sodium pentobarbital (Sigma) anesthesia, and all efforts were made 151 
to minimize animal suffering. 152 
 153 
Rat DRG neuron culture. Dorsal root ganglion (DRG) neurons were obtained 154 
from adult Sprague-Dawley rats (provided by Experimental Animal Center of Hebei 155 
Province) based on the protocol described previously (Du X et al., 2014). Briefly, the 156 
ganglia were digested at 37°C with collagenase (2 mg/ml) with dispase (7.5 mg/ml) 157 
for 30 min. Ganglia were then mechanically triturated and washed twice with DMEM 158 
supplemented with 10% fetal calf serum. Thereafter, the DRG neurons were plated on 159 
poly-D-lysine-coated glass cover slips. 160 
 161 
Quantitative PCR. Total RNA was extracted using a commercial RNA isolation 162 
kit (RNAiso, Takara). Isolated RNA was dissolved in 20 ȝl DEPC-treated water and 163 
reverse-transcribed using an RT reagent kit (PrimeScript with gDNA Eraser, Takara) 164 
and a thermal cycler (Mastercycler, Eppendorf). Quantitative PCR reaction was 165 
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performed using a kit (SYBR Premix Ex TaqII [Tli RNase H Plus], Takara), and the 166 
fluorescent DNA was detected and quantified with an FQD-48A(A4) system (BIOER). 167 
The PCR products were also run on a 2% agarose gel and were visualized using a gel 168 
imager (TFP-M/WL, Vilber Lourmat). For qPCR analysis, the following specific 169 
primers were used: 170 
Nav1.7-Forward: GCTCCAAGGACACAAAACGAAC,  171 
Nav1.7-Reverse: ATCAGACTCCCCAGGTGCAAT; 172 
Nav1.8-Forward: GACCCTTTCTACAGCACACACC,  173 
Nav1.8-Reverse: AAGTCCAGCCAGTTCCACG; 174 
Nav1.9-Forward: GCCCCTTCACTTCCGACT, 175 
Nav1.9-Reverse: GTCTTCCAGAGGCTTCGCTAC; 176 
GAPDH-Forward: CCAGCCTCGTCTCATAGACA, 177 
GAPDH-Reverse: CGCTCCTGGAAGATGGTGAT 178 
 179 
Luciferase reporter assay. The Stat3 luciferase reporter vector was designed to 180 
measure the binding of transcription factors to the enhancer, and was transfected into 181 
HEK293 cells with Lipofectamine2000 reagent (Invitrogen).  182 
Fragments of rat Scn9a, Scn10a and Scn11a gene were amplified by PCR with 183 
following primers: 184 
Forward-GGCTCGAGAGCTTAAGGAAAGGAGGGTA,  185 
Reverse-GTAAGCTTTTTCCCCTTTGACTCCTTAC; corresponding to the promotor 186 
region of Scn9a (-286/+306). 187 
Forward-GGCTCGAGCCGTAGTAAGACCCTGCCTTG,  188 
Reverse-GTAAGCTTGAGACCCCAGCTCTGCAAAAC; corresponding to the 189 
promotor region of Scn10a (749/+124) . 190 
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Forward-GGCTCGAGCTTCACATGGTTGATCCATC  191 
Reverse-GTAAGCTTATTCTCGCTCTTGGCAGTA; corresponding to the promotor 192 
region of Scn11a (-51/+556 regions). 193 
Amplified fragments were digested with appropriate restriction enzymes and cloned 194 
into pGL3 Basic (Promega). Luciferase activity was measured using a Dual 195 
Luciferase Assay Kit (Promega). Specific promoter activity was expressed as the 196 
relative activity ratio of firefly luciferase to Renilla luciferase. 197 
 198 
Western Blot. The DRG neuron lysates were prepared with RIPA lysis buffer. 199 
Equal amounts of protein were separated by sodium dodecyl sulfate polyacrylamide 200 
gel electrophoresis (SDS-PAGE) and electrotransferred to a polyvinylidene fluoride 201 
membrane. Membranes were blocked with 5% non-fat dairy milk and incubated with 202 
primary antibodies against Nav1.7 (1:500, Alomone), Nav1.8 (1:500, Abcam), Nav1.9 203 
(1:200, Abcam), p-Jak1 (1:1000, Affinity), p-Jak2 (1:1000, Affinity), p-Jak3 (1:1000, 204 
Affinity), p-stat3 (1:1000, Epitomics), p-Stat5a (1:1000, Affinity) at 4°C overnight. 205 
This was followed by incubation with IRDye800-conjugated secondary antibody 206 
(1:20,000, Rockland) for 1 h at room temperature and subsequent scanning with the 207 
Odyssey Infrared Imaging System (LI-COR Biosciences). The integrated intensity for 208 
each detected band was determined using Odyssey Imager software (v3.0). 209 
 210 
Immunohistochemistry. Sections from human osteosarcoma or chondroma 211 
tissues were blocked with 0.3% hydrogen peroxide, followed by preincubation with 5% 212 
normal goat serum and then incubation with primary antibodies against GM-CSF 213 
(1:200, Pepro Tech) at 4 °C overnight. Next, the sections were incubated with the 214 
biotinylated secondary antibody, followed by streptavidin-horseradish peroxidase and 215 
diaminobenzidine, and then counterstained with hematoxylin. Staining intensities 216 
were determined by measurement of the integrated optical density (IOD) by light 217 
microscopy using a computer-based Image-Pro Morphometric System. 218 
 219 
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Electrophysiology. Action potentials were recorded from dissociated rat small 220 
GLDPHWHU '5* QHXURQV  ȝm) under current clamp using an Axopatch 200B 221 
amplifier and a Digidata 1322A converter (Axon Instruments). Pipettes (3± 0ȍ222 
were filled with solution containing (in mM): KCl 150, MgCl2 5, HEPES 10, pH 7.4 223 
adjusted with KOH. The bath solution contained (in mM): NaCl 160, KCl 2.5, MgCl2 224 
1, CaCl2 2, glucose 10, HEPES 20 and pH 7.4 adjusted with NaOH. Small DRG 225 
neurons were examined for evoked activity with a series of 1-s current injections from 226 
0 pA to 500 pA in 50 pA increments. The rheobase currents were determined by the 227 
first action potential elicited by a series of depolarizing current injections that 228 
increased in 5 pA increments. The following values were measured in this study: 229 
resting membrane potential (RMP), threshold potential (TP), AP amplitude, 230 
depolarization rate (V/s). 231 
Sodium currents were recorded from these small diameter DRG neurons under 232 
the voltage clamp mode in a whole-cell configuration. Pipettes (3±4 0ȍ) were filled 233 
with solution containing (in mM): 70 CsCl, 30 NaCl, 30 TEA-Cl, 10 EGTA, 1 CaCl2, 234 
2 MgCl2, 2 Na2ATP, 0.05 GTP, 10 HEPES, and 5 glucose, pH 7.3 with CsOH. The 235 
bath solution for DRG neurons was (in mM): 80 NaCl, 50 choline-Cl, 30 TEA-Cl, 2 236 
CaCl2, 0.2 CdCl2, 10 HEPES, and 5 glucose, pH 7.3 with NaOH. The acquisition rate 237 
was 20 kHz and signals were filtered at 5 kHz. Series resistances were compensated 238 
by 80%. Currents were elicited by a 40 ms pulses from a holding potential of -120 239 
mV to test potentials between -80 mV and +40 mV in 5 mV increments. The 240 
TTX-resistant (TTX-R) sodium currents (including both Nav1.9 and Nav1.8 currents) 241 
were recorded in the presence of 300 nm TTX in the external solution. The 242 
TTX-sensitive (TTX-S) sodium currents were obtained by digital subtraction of the 243 
TTX-R sodium currents from the total currents. Nav1.8 currents were then elicited by 244 
a prepulse of -70 mV for 500 ms before the test potentials from -80 mV to +40 mV in 245 
5 mV increments in the same neuron. The Nav1.9 currents were obtained by digital 246 
subtraction of the Nav1.8 currents from the TTX-R sodium currents (based on 247 
protocols from (Qiu et al., 2016). 248 
 249 
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Rat model of tumor-evoked pain. The Walker 256 carcinosarcoma breast cancer 250 
cells were provided by Shanghai Cell Bank of the Chinese Academy of Sciences. 251 
Wistar rats were injected intra-peritoneally with the Walker 256 cancer cells 0.5 ml 252 
(2 × 107 cells/ml and 6±7 days later ascitic fluid was extracted. Sprague Dawley rats 253 
(180-200 g) were anesthetized by intraperitoneal injection of sodium pentobarbital 254 
(60-80 mg/kg). The right leg was shaved and the skin was disinfected with 70% (v/v) 255 
ethanol. A 1-cm-long rostro-caudal incision was made in the skin over the lower 256 
one-third of the tibia for exposure with minimal damage to muscles and nerves. The 257 
medullary canal was approached by inserting a 23-gauge needle proximally through a 258 
hole drilled in the tibia. The needle was then replaced with a 10-ȝO PLFURLQMHFWLRQ259 
syringe containing the cells to be injected. A 5-ȝO YROXPH RI :DONHU  FHOOV260 
(4×106/ml) or boiled cells (sham group) were injected into the bone cavity. After a 261 
2-min delay to allow cells to fill the bone cavity, the syringe was removed and the 262 
hole was sealed using bone wax. In some experiments, antibody against GM-CSF (10 263 
Pg, SCBT), antibody GM-CSFR (10 Pg, SCBT), GM-CSF antagonist, E21R (25 264 
ȝJ/ȝl, 3 ȝl, Life Tein LLC) or vehicle was injected in the vicinity of the tibia bone. 265 
The wound was closed using 1-0 silk threads and dusted with penicillin powder. The 266 
rats were allowed unrestricted movement in their cages after recovery and their 267 
general condition was monitored during the experiment.  268 
 269 
Focal application of drugs to DRG in vivo. All surgical procedures were 270 
performed under deep anesthesia with an i.p. injection of pentobarbital sodium (60-80 271 
mg/kg). A DRG cannula for focal application of substances to DRG was implanted as 272 
previously described (Du X et al., 2017). Briefly, a midline incision was made at the 273 
L4-L6 spinal level of adult male rats (Sprague Dawley; 180-200 g), and the L5 was 274 
identified at the midpoint of a link between both sides of the iliac crest. A 0.8-mm 275 
hole (~1 mm off the inferior edge of the transverse process) was drilled through the 276 
transverse process over the L5 DRG. Approaching of a ganglion was verified by the 277 
twitch of the paw. A hooked stainless steel blunt-tip cannula (inner diameter 0.64 mm, 278 
length 4 mm) was forced into the hole and connected to a polypropylene tube (inner 279 
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diameter 0.41 mm, length 4.5 mm). The incision was closed with sutures, and the 280 
cannula was firmly fixed in place with dental cement. Intramuscular injection of 281 
benzylpenicillin (19 mg/0.1 ml) was given immediately after surgery. Postoperatively, 282 
rats were housed individually in plastic cages with sawdust flooring and supplied with 283 
water and food ad libitum. Animals were left to recover for at least 24 hours before 284 
the experiments were carried out. Animals developing signs of distress were 285 
humanely sacrificed.  286 
 287 
Antisense oligonucleotide knockdown. On the second day after DRG cannula 288 
implantation, rats were given through the cannula the antisense oligodeoxynucleotides 289 
(AS ODNs) against Scn9a, Scn10a, Scn11a, Jak2, Stat3 or Stat5 (each at 12.5 ȝg in 5 290 
ȝl). The AS ODNs were given consecutively twice a day for 4 days. Mismatched 291 
ODNs were also given at matched time points. On the fifth day, mechanical and 292 
thermal sensitivities were assessed at 1 h, 2 h, 5 h, 12 h, and 24 h after the focal DRG 293 
application of GM-CSF (5 ȝl) or saline (5 ȝl) , respectively. Seven groups of animals 294 
were tested, injected as follows: 295 
Group   type of ODN pre-treatment  treatment type 296 
1   mismatched ODN    GM-CSF or saline    297 
2   AS ODN Scn9a     GM-CSF or saline 298 
3   AS ODN Scn10a     GM-CSF or saline 299 
4   AS ODN Scn11a     GM-CSF or saline 300 
5   AS ODN Jak2     GM-CSF or saline 301 
6   AS ODN Stat3     GM-CSF or saline 302 
7   AS ODN Stat5a     GM-CSF or saline 303 
 304 
The following specific ASO were used: 305 
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Mismatched ODN: TCACCCAGCACCCCCAACACATAGTT 306 
ASO- Scn9a: CTGGATCAACATGGTCTTCA 307 
ASO- Scn10a: CCAGAACCAAGCACAGAGGA 308 
ASO- Scn11a: CACCATCTGCATCATCATCA 309 
ASO-Jak2: AAGGTACAGATTCCGCAGGT 310 
ASO-Stat3:ACATGGAGGAGTCCAACAAC 311 
ASO-Stat5a:TCTCAGTTCAGCGTTGGCAG 312 
 313 
Mechanical hyperalgesia. Threshold sensitivity to mechanical stimuli was 314 
assessed using the von Frey method as described previously (Chaplan et al., 1994). 315 
Briefly, calibrated nylon filaments (Von Frey hair, Stoelting Co,) with different 316 
bending forces were applied to the midplantar surface of the right hind paw of the rats. 317 
The filaments were applied starting with the softest and continuing in ascending order 318 
of stiffness. A brisk withdrawal of the right hind limb was considered a positive 319 
response. 320 
 321 
Thermal hyperalgesia. The paw withdrawal latency in response to heat was 322 
tested using the Hargreaves method on the right hind paw of the rats using a radiant 323 
heat lamp source (Mengtai Technology Co., Ltd.). The intensity of the radiant heat 324 
stimulus was maintained at 20%. The time to withdrawal of the right hind paw (elapse 325 
time) was recorded. 326 
 327 
Blinding and randomization. In all in vivo experiments when animal behavior 328 
test and drug administration were involved, experiments were conducted on the basis 329 
of a blind and randomized design. To achieve this, two experimenters performed 330 
every tests: one experimenter was in charge of drug injections and group 331 
randomization; second experimenter, blinded to the drug administration and grouping 332 
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schedules, conducted the mechanical and thermal sensitivity measurements. 333 
 334 
Statistics and analysis. All data are given as mean ± SEM. Differences between 335 
groups were assessed by paired or unpaired t test. Comparisons of the behavioral data 336 
between groups at each individual time point were conducted using a two-way 337 
ANOVA followed by Bonferroni post hoc tests. Comparisons of the number of action 338 
potential between groups at each injected currents were conducted using a two-way 339 
ANOVA followed by Bonferroni post hoc tests. Differences were considered 340 
significant at P   6WDWLVWLFDO DQDO\VHV ZHUH SHUIRUPHG XVLQJ 2ULJLQ3UR 341 
(Originlab Corp.).  342 
 343 
Results 344 
GM-CSF plays a crucial role in bone metastases cancer pain. Osteosarcoma is 345 
the most common form of primary bone cancer, in which pain is the most common 346 
symptom and is seen in 85% of patients (Yoneda et al., 2015). Osteochondroma is the 347 
most common benign bone tumor and the majority of osteochondromas form an 348 
asymptomatic hard immobile painless palpable mass (de Mooij et al., 2012). We first 349 
collected tumor tissue from osteosarcama and osteochondroma patients after surgery, 350 
and compared the expression levels of GM-CSF in these two tumor tissue types. The 351 
H&E staining shows typical characteristics of a cancerous (Fig. 1A, low left) and a 352 
benign (Fig. 1A upper left) bone tissue. Interestingly, osteosarcoma biopsy samples 353 
demonstrated a dramatically increased levels of GM-CSF, as compared to these seen 354 
in osteochondroma samples, as revealed with immunohistochemistry (Fig. 1A right 355 
panels; summarized in Fig. 1B, n = 8, *P < 0.05).  356 
To explore the role of GM-CSF in bone cancer pain, we first established the bone 357 
metastases cancer pain model induced by the implanted Walker 256 carcinoma cells. 358 
Consistent with previous reports (Wang et al., 2011), mice with tumors in the tibia 359 
bone displayed a significantly lower withdrawal thresholds for mechanical stimuli and 360 
a shortened withdrawal latencies for thermal stimuli at 3-21 days after tumor cell 361 
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injection (Fig. 1C, 1D). To assess the role of GM-CSF in these behavioral 362 
manifestations of pain hypersensitivity, we injected a mutant GM-CSF peptide with 363 
the glutamate-to-arginine substitution at the position 21 of a rat GM-CSF peptide 364 
sequence (E21R). E21R acts as a competitive antagonist of GM-CSF and can 365 
neutralize some of its biologic actions (Iversen et al., 1996), however its effect on 366 
GM-CSF-mediated pain has not been tested before. E21R was injected in the vicinity 367 
of the tibia bone where the cancer cells had been implanted (see Methods). Treatment 368 
of the bone cancer rats with E21R significantly alleviated both mechanical and 369 
thermal hyperalgesia, respectively (Fig. 1C). The reduction of hyperalgesia was 370 
registered starting from day 7 after the establishment of the bone cancer model and 371 
lasted for the duration of observation (21 days). To further validate the role of 372 
GM-CSF in the bone cancer pain, we also used antibodies against GM-CSF and 373 
GM-CSF receptor (GM-CSFR). Injection of anti-GM-CSF and anti-GM-CSFR  374 
antibodies also produced strong anti-hyperalgesic effect, the anti-GM-CSFR antibody 375 
was particularly efficacious, resulting in significantly stronger anti-hyperalgesia, as 376 
compared to E21R (Fig. 1C). These results indicate that GM-CSF is indeed involved 377 
in the bone cancer pain development, which is in agreement with a previous report 378 
that the bone cancer pain was attenuated following a specific knockdown of GM-CSF 379 
receptors in L4-L5 DRG of mice (Schweizerhof et al., 2009).  380 
To further attest that GM-CSF is pro-algesic and the primary afferent sensory 381 
nerve are the targeted sites of GM-CSF action, we evaluated the effect of direct focal 382 
GM-CSF infusion into the L5 DRG on pain-related behavior in naïve rats (Fig. 1D). 383 
Compared with the vehicle-treated rats, GM-CSF induced significant dose-dependent 384 
thermal and mechanical hyperalgesia which persisted for at least 24 hrs after injection. 385 
Indeed, focal injection of GM-CSF (20 - 200 ng) via the DRG cannula significantly 386 
increased sensitivity of rats to thermal and mechanical stimuli as measured with the 387 
Hargreaves and Von Frey tests, respectively (P < 0.05). The nociceptive responses in 388 
rats received 2 ng of GM-CSF also showed a tendency towards sensitization but these 389 
effects did not reach statistical significance.  390 
 391 
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GM-CSF increase the excitability of small-sized DRG neuron. The fact that 392 
GM-CSF enhanced pain sensitivity when injected into DRG suggests that GM-CSF 393 
might directly sensitize nociceptors by increasing their excitability. To test this 394 
hypothesis, we performed current clamp recordings from the cultured DRG neurons in 395 
control conditions and after 24 hrs treatment with GM-CSF (200 ng/ml). For this 396 
study, smDOO GLDPHWHU   ȝM) DRG neurons were selected as these are 397 
predominantly nociceptors (Zheng et al., 2013). AP firing was induced by trains of 398 
depolarizing current step from +50 to +500 pA, injected with a 50 pA increment. 399 
GM-CSF significantly increased the number of APs induced by the depolarizing 400 
current pulses from 100 to 500 pA (Fig. 2A, B). GM-CSF also significantly lowered 401 
the rheobase currents (depolarization current threshold (CT) for eliciting the 1st action 402 
potential) from 198.6 ± 9.8 pA (n = 63) to 83.1 ± 2.5 pA (n = 39, P < 0.05); the action 403 
potential threshold voltage (TP) was also significantly decreased from -18.7 ± 0.5 mV 404 
(n = 23) to -20.4 ± 0.6 mV (n = 22, P < 0.05). However, the resting membrane 405 
potential was not significantly changed (Fig. 2C, 1D). We also measured the effect of 406 
GM-CSF treatment on other properties of evoked APs such as AP amplitude (mV) and 407 
rate of depolarization (V/s), which are summarized in Table 1. Together, the above 408 
data indicate that GM-CSF increases intrinsic neuronal excitability of primary sensor 409 
neurons associated with pain. 410 
 411 
GM-CSF increases activity and expression level of Nav1.7 Nav1.8 and Nav1.9 412 
sodium channels. The sensitizing effect of a single focal in vivo injection of GM-CSF 413 
was long-lasting (Fig. 1E), in addition, intracellular action of GM-CSFRs has long 414 
been linked to transcriptional effects via the activation of Jak-Stat pathway. Thus, we 415 
hypothesized that the sensitizing effect of this growth factor might be mediated by 416 
changes in the expression of some intrinsic regulator(s) of excitability. Thus, to 417 
further explore the mechanisms for GM-CSF-induced hyperactivity of DRG 418 
nociceptors, we screened the effect of GM-CSF on ion channels which have been 419 
implicated in modulation of resting excitability of DRG neurons (Liu et al., 2010; 420 
Zheng et al., 2013; Qiu et al., 2016; Isensee et al., 2017; Du et al., 2018). We tested 421 
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the effect of treatment of cultured DRG neurons with 200 ng/Pl GM-CSF (24 hrs) on 422 
the mRNA abundance of the following ion channel genes: Scn9a (Nav1.7), Scn10a 423 
(Nav1.8), Scn9a (Nav1.9), Kcnd2 (Kv4.2), Ano1 (TMEM16A), P2rx3 (P2X3), Kcng2 424 
(Kv7.2), Kcnq3 (Kv7.3). Among the transcripts tested, only the mRNAs of 425 
voltage-gated sodium channels Nav1.7, Nav1.8 and Nav1.9 were elevated (Figure 3A). 426 
Additionally, the mRNAs of Nav1.7-1.9 expression were elevated by day 7 in DRGs 427 
from bone cancer rats relative to those from sham controls (Figure 3B). 428 
Next, we examined the effects of GM-CSF treatment on the current density of 429 
voltage-gated sodium currents in DRG neurons. Total, TTX- sensitive (TTX-S) and 430 
TTX-resistant Na+ currents were recorded (see Method) using whole-cell patch clamp. 431 
After pretreatment of DRG neurons with GM-CSF (200 ng/ml; 24hrs), the peak 432 
current density of total Na+ currents was increased from -101.0 ± 8.8 (pA/pF) (n = 44) 433 
to -155.8 ± 9.9 (pA/pF) (n = 32) at -10 mV; the peak current density of TTX-S 434 
currents (mainly Nav1.7 currents) was increased from -58.0 ± 6.5 (pA/pF) (n = 66) to 435 
-100.6 ± 4.7 (pA/pF) (n = 43) at -20 mV; the peak current density of TTX-R currents 436 
was increased from -56.5 ± 4.9 (pA/pF) (n = 66) to -75.5 ± 5.7 (pA/pF) (n = 43) at -10 437 
mV (Fig 3C).  438 
The TTX-R Na+ currents were further separated into Nav1.8-rich currents and 439 
Nav1.9-rich current fractions (see Method). After pretreatment of DRG neurons with 440 
GM-CSF, the peak current density of Nav1.8-rich current fraction was increased from 441 
-44.5 ± 4.5 (pA/pF) (n = 55) to -60.1 ± 4.4 (pA/pF) (n = 36) at 0 mV; the Nav1.9-rich 442 
current fraction was increased from -20.2 ± 1.4 (pA/pF) (n = 53) to -29.4 ± 0.9 (pA/pF) 443 
(n = 36) at -20 mV (Fig. 3C). In sum, GM-CSF significantly increased the current 444 
amplitudes of nociceptor-specific Nav1.7 Nav1.8 and Nav1.9 currents. Furthermore, 445 
the protein expression levels of Nav1.7, Nav1.8 and Nav1.9 channel in DRG neurons 446 
were also significantly increased after incubation with GM-CSF (200 ng/ml; 18 h; Fig. 447 
3D). 448 
 449 
Down-regulation of Nav1.7-Nav1.9 channels alleviates GM-CSF induced pain. 450 
To investigate whether the up-regulation of Nav1.7, Nav1.8 and Nav1.9 channels 451 
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contributes to the GM-CSF-mediated pain, we performed unilateral in vivo 452 
knockdown of individual sodium channel subunit in rats using the anti-sense 453 
oligodeoxynucleotides (AS ODNs). AS ODNs against Scn9a, Scn10a and Scn11a (or 454 
a control mismatched ODN) were injected into the L5 DRG via the DRG cannula to 455 
offset the up-regulation of these sodium channels, and then the effect of GM-CSF on 456 
pain behavior was examined. The knockdown efficiency was measured first; for this, 457 
the L5 DRGs were extracted following focal injection of saline, GM-CSF, AS ODN + 458 
Saline, AS ODN + GM-CSF, and then the mRNA expression levels of Scn9a, Scn10a 459 
and Scn11a were analyzed by quantitative PCR. In agreement with previous data, the 460 
mRNA expression levels of Scn9a, Scn10a and Scn11a in DRG neurons were 461 
significantly increased after GM-CSF injection, and importantly, these increase were 462 
totally reversed by respective AS ODNs (Fig. 4A). Consistent with our earlier 463 
conclusion that up-regulation of Na1.7-Nav1.9 channels is a crucial factor in 464 
GM-CSF-induced hypersensitivity, AS ODNs against Scn9a, Scn10a and Scn11a 465 
significantly alleviated both mechanical and thermal hypersensitivity developed after 466 
the focal DRG application of GM-CSF (Fig. 4 B-C). 467 
 468 
GM-CSF up-regulates Nav1.7-Nav1.9 channel expression via the Jak2-Stat3 469 
signaling pathway. GM-CSF receptor is abundantly expressed in DRG (Schweizerhof 470 
et al., 2009). Thus we hypothesized that the GM-CSF induced up-regulation of 471 
Nav1.7-Nav1.9 in DRG neurons could be mediated by the GM-CSF receptor and the 472 
related cellular signaling pathway. To test this, we focused on the Jak-Stat3/5 pathway 473 
since this is the key pathway for GM-CSF action in hematopoietic cells (Lilly et al., 474 
2001). Activated and phosphorylated states of Jak1, Jak2, Jak3, Stat3 and Stat5 were 475 
first measured in DRG neurons. As shown in Fig. 5A, after incubation of DRG 476 
cultures with GM-CSF for 25 min, phosphorylated Jak2 and Stat3 were significantly 477 
increased, but the level of phosphorylated Jak1 was not changed; phosphorylated Jak3 478 
and Stat5 were not detected. These results indicate that GM-CSF is able to activate 479 
Jak2-Stat3 signaling pathway in DRG neurons. Is this activated Jak2-Stat3 signaling 480 
pathway responsible for GM-CSF±induced up-regulation of Nav1.7-Nav1.9 in DRG 481 
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neurons? To test this, the acutely disassociated DRG neurons were incubated with 482 
GM-CSF with and without blockers of Jak2-Stat3 signaling pathway, AG490 (10 PM) 483 
and stattic (20 PM). Both compounds prevented up-regulation Nav1.7-Nav1.9 mRNA 484 
by GM-CSF (Fig 5B).  485 
As Stat3 was previously demonstrated to function as a transcriptional activator 486 
(Sharma et al., 2018), thus, we designed a luciferase reporter assay to determine if 487 
Stat3 acts to regulate Nav1.7-Nav1.9 transcription. Scn9a-Scn11a promoter regions 488 
(relative to the transcription start site) were cloned into a luciferase reporter vector 489 
(pGL3 Basic plasmid), such that luciferase expression is driven by either of the 490 
Scn9a-Scn11a  promoter sequences. We transfected these DNA constructs and either 491 
a control pcDNA3.1 plasmid or a pcDNA3.1-stat3 plasmid into HEK293 cells and 492 
measured the resulting luciferase activity. Luciferase activity in cells co-expressed 493 
with Scn9a, Scn9a or Scn11a promoter fragments and Stat3 was 1.57 ± 0.14 (n = 4, P 494 
< 0.05), 1.5 ± 0.05 (n = 4, P < 0.05), 1.5 ± 0.15 (n = 4, P < 0.05) folds higher than that 495 
in cells co-expressed with Scn9a, Scn9a or Scn11a promoter fragments and the 496 
control pcDNA3.1 plasmid (Fig. 5C). These results implicate an important role for 497 
Stat3 in promoting Nav1.7, Nav1.8, and Nav1.9 gene expression.  498 
Finally we assessed whether down regulation of Jak2-Stat3 signaling pathway 499 
would inhibit GM-CSF-induced up-regulation of Nav1.7-Nav1.9 and subsequently the 500 
pain behaviors. To this end, AS ODNs against Jak2 and Stat3 were injected in DRG 501 
(L5) via DRG cannula as described above. AS ODNs against Jak 2 (Fig. 5D) and 502 
Stat3 (Fig. 5E) but not against Stat5 (Fig. 5F) reduced basal mRNA levels of 503 
Scn9a-Scn11a and reversed the GM-CSF-induced up-regulation of Scn9a-Scn11a 504 
mRNA levels. Consistent with these results, AS ODNs against Jak2 (Fig. 5G) and 505 
Stat3 (Fig. 5H) but not AS ODNs against Stat5 (Fig. 5I) prevented the development of 506 
the mechanical and thermal hyperalgesia produced by focal in vivo application of 507 
GM-CSF via the DRG cannula (Fig. 5G, H, I). AS ODNs against Jak2, Stat3 and 508 
Stat5 did not significantly affect the mechanical and thermal sensitivity in rats without 509 
GM-CSF treatment (in accord with previous findings suggesting that Nav1.7,  510 
Nav1.8 or Nav1.9 knockout or knockdown does not significantly affect threshold 511 
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sensitivity in mice (Minett et al., 2013; Miao et al., 2010; Lolignier et al., 2011). 512 
Taken together, these results identified Jak2-Stat3-mediated up-regulation of 513 
Nav1.7-Nav1.9 channels as a key signaling pathway involved in the development of 514 
GM-CSF induced pain. 515 
 516 
Discussion 517 
In this study we demonstrate that GM-CSF promotes bone cancer-associated pain 518 
by enhancing excitability of DRG neurons via the Jak2-Stat3-mediated upregulation 519 
of expression of nociceptor-specific voltage-gated sodium channels. First, we show 520 
that GM-CSF is highly expressed in osteosarcoma biopsy samples from human 521 
patients. Second, we demonstrate that the competitive antagonist of GM-CSF, 522 
GM-CSF (E21R) as well as the antibodies against GM-CSF or GM-CSFR are able to 523 
reduce both thermal and mechanical hyperalgesia in a rat model of bone cancer. Third, 524 
we show that GM-CSF increases excitability of peripheral nociceptors by 525 
upregulating functional expression of nociceptor-specific Na+ cannels, Nav1.7-Nav1.9. 526 
Furthermore, using unilateral in vivo gene knockdown we further demonstrate that 527 
Na+ channel upregulation is indeed a necessary step in the development of GM-CSF 528 
induced pain in vivo. Finally, using a set of genetic manipulations and assays, we 529 
delineated a molecular mechanism for GM-CSF induced initiation of pain in bone 530 
cancer: up-regulation of functional Nav1.7, Nav1.8 and Nav1.9 channel activity 531 
though the Jak2-Stat3 mediated activation of Scn9a, Scn10a and Scn11a gene 532 
transcription.  533 
Several recent studies implicated contribution of GM-CSF to different types of 534 
pain, including cancer pain, neuropathic, inflammatory and osteoarthritic pain. (Cook 535 
et al., 2012; Cook et al., 2013; Nicol et al., 2018). Yet, the exact mechanism and main 536 
molecular steps of the pro-algesic action of GM-CSF remained elusive. Our study fills 537 
this gap providing a mechanistic framework for the effect.  538 
Increased excitability of nociceptive neurons is a fundamental mechanism for 539 
pain. In turn, changes in excitability are ultimately linked to altered ion channel 540 
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activity. Thus, in this study we focused on ion channels controlling excitability of 541 
DRG neurons. All results pinpoint Nav.7-Nav1.9 channels as key determinants of the 542 
GM-CSF proalgesic action. 1) GM-CSF increased levels of Scn9a, Scn10a and 543 
Scn11a but not the other key ion channels tested. 2) Consistent with above results, 544 
protein level of Nav1.7-Nav1.9 and the appropriate Na+ current fractions in 545 
nociceptive DRG neurons were also increased by GM-CSF. 3) Changes of DRG 546 
neuron excitability induced by GM-CSF were consistent with elevated Na+ channel 547 
activity: lowered rheobase, lowered threshold potential, but no significant change in 548 
resting membrane potential. Notably, GM-CSF did not change amplitude of M-type 549 
K+ current, which is another type of ion channels, important for setting resting 550 
excitability parameters of a neuron (Table1). 4) Down regulation of Nav1.7-Nav1.9 551 
with AS ODNs alleviated GM-CSF-induced pain behavior. While the latter evidence 552 
does not directly prove involvement of these Nav channels in GM-CSF-induced pain 553 
specifically (since down regulation of them will probably inhibit any type of pain 554 
behavior anyway), the combined evidence implicate Nav channel mechanism as the 555 
most plausible and straightforward explanation for GM-CSF induced pain nonetheless. 556 
However, contribution of other mechanisms to the GM-CSF induced pain cannot be 557 
ruled out at present; indeed involvement of other mediators, including Ccl5, Ccl3 and 558 
Il1a has been reported (Stosser et al., 2011). 559 
We provide evidence that Jak2-Stat3 signaling pathway contributes to GM-CSF 560 
mediated up-regulation of Nav channels described above and, thus, to hyperalgesia 561 
associated with high GM-CSF levels, e.g. as observed in bone cancer. Activation of 562 
Jak by GM-CSF leads to activation of the Stat family transcription factors, which 563 
dimerize and translocate to the nucleus and modulate gene expression (Choi et al., 564 
2011). In hematopoietic cells, GM-CSF exerts its biological functions mainly through 565 
activation of Jak2, which then activates Stat3 and Stat5 but not Stat2, Stat4 or Stat6 566 
(Zgheib et al., 2013). However, the signal transduction pathways mediated by 567 
GM-CSF and its receptors are cell-type specific and may differ significantly 568 
(Valdembri et al., 2002). In the present study we found that in DRG neurons Jak2 and 569 
Stat3 are selectively phosphorylated following the GM-CSF treatment; 570 
phosphorylated Jak1 was not affected and phosphorylated Jak3 and Stat5 were not 571 
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fund at all. Consistent with these results, very low levels of Jak3 and Stat5 mRNA in 572 
DRG neurons were retrieved using the iBrain big data platform (Li et al., 2016). Thus, 573 
Jak2-Stat3 is likely to be the dominant signaling pathway for GM-CSF to exert its 574 
function in DRG neurons. 575 
Luciferase reporter assay provided strong evidence indicating that Stat3 is able to 576 
bind to the promoter regions of Scn9a, Scn10a and Scn11a genes to enhance their 577 
transcription. In accordance with this observation, down-regulation of Jak2 and Stat3 578 
with anti-sense oligodeoxynucleotides reversed the GM-CSF induced elevation of 579 
mRNA expression level of these Nav channels. Importantly, these anti-sense 580 
oligodeoxynucleotides against Scn9a-Scn11a also alleviated the GM-CSF elicited 581 
pain behavior. These results not only describe a clear mechanism for how 582 
Nav1.7-Nav1.9 channels are up-regulated by GM-CSF signaling pathway, but also 583 
indicate that specific Jak-Stat pathway could be targeted for pain therapeutics.   584 
GM-CSF is used clinically for treatment of myelodysplastic syndromes, aplastic 585 
anemia, tumor radiotherapy and chemotherapy-induced neutropenia (Garcia et al., 586 
2014).The most severe adverse reaction to these GM-CSF therapies is bone pain and 587 
the  incidence is reported to reach up to 90% (Stosser et al., 2011). These clinical 588 
observations align very well with our results showing that GM-CSF induces pain 589 
behavior in rats when injected to DRG at a concentration of 20 ng/ml GM-CSF, which 590 
is lower than the blood concentration of after a single-dose administration of 591 
GM-CAF in humans (~600 ng/ml; (Alexanderet et al., 2016)). Thus, clinically 592 
administered GM-CSF reaches sufficient blood concentrations to be able to sensitize 593 
bone periosteal nerves and nociceptive neurons through the mechanism described 594 
here. 595 
In summary, in this study provides mechanistic explanation for the role of 596 
GM-CSF in pain, specifically in pain associated with the bone cancer and with the 597 
GM-CSF-based therapies. This novel mechanism should be considered as a potential 598 
target for future pain treatments. 599 
  600 
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Figure legends 741 
Figure 1. Role of GM-CSF in bone metastases cancer pain. (A) High expression 742 
level of GM-CSF in osteosarcoma tissue sample. H&E staining of chondroma and 743 
osteosarcoma is shown on the left; immunohistochemical staining for GM-CSF 744 
indicated by arrows in chondroma and osteosarcoma is shown on the right. (B) 745 
Summary results for immunohistochemical staining for GM-CSF (n = 8 per group, 746 
unpaired t-test: t=5.69, *p=0.0013). (C). Effect of antibodies against GM-CSF or 747 
GM-CSFR (10 ȝJ) and GM-CSF analogue E21R (a competitive antagonist of 748 
GM-CSF, 25 ȝJ/ȝl, 3 ȝl) on mechanical (left panel) and thermal (right panel) 749 
nociceptive responses in bone cancer pain model of rats. The mechanical paw 750 
withdrawal threshold and thermal paw withdrawal latency were measured at 3, 7, 11, 751 
14, 17, and 21 days for the control group (black line + squares), the bone cancer group 752 
(red line + circles), the bone cancer + antibody against GM-CSF group (blue line + 753 
triangles), the bone cancer + antibody against GM-CSFR group (pink line + triangles) 754 
and the bone cancer + E21R group (green line + triangles). Two-way ANOVA 755 
followed by Bonferroni post hoc tests revealed a significant effect of treatment 756 
(F(4,150)=29.49, p=0) and time (F(5,150)=5.06, p<0.0001) but no interaction between the 757 
two (F(20,150)=0.71, p=0.81) for the left panel; a significant effect of treatment 758 
(F(4,240)=15.10, p<0.0001), time (F(4,240)=2.56, p=0.028) and an interaction between the 759 
two (F(20,240)=2.20, p=0.003) for the right panel; *P < 0.05 as compared to sham group; 760 
#P < 0.05 with respect to the corresponding bone cancer group. (D) Dose-dependent 761 
effects of GM-CSF on paw withdrawal threshold to mechanical stimulus (left panel) 762 
and on paw withdrawal latency to noxious heat (right panel) at 1 h, 2 h, 5 h, 12 h and 763 
24 h following focal DRG application via DRG cannula. Number of experiments is 764 
indicated as n in each panel. Two-way ANOVA followed by Bonferroni post hoc tests 765 
revealed a significant effect of dose (F(3,345)=29.30, p<0.0001) but not of time 766 
(F(3,345)=0.15, p=0.96), nor an interaction between the two (F(12,345)=0.37, p=0.97) for 767 
the left panel. For the right panel, there was a significant effect of dose (F(3,350)=70.95, 768 
p=0) and an interaction between dose and time (F(12,350)=3.71, p<0.0001) but effect of 769 
time did not reach significance (F(3,350)=2.09, p=0.08). *P < 0.05 as compared to the 770 
vehicle saline). 771 
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Figure 2. Effect of GM-CSF on the excitability of small-sized DRG neurons. (A) 772 
Representatives of action potentials evoked by depolarizing current pulse (left), 773 
recorded from small-sized DRG neurons. (B) Summary results for the effect of 774 
GM-CSF on numbers of action potential induced by increasing amplitudes of 775 
depolarizing currents. Two-way ANOVA followed by Bonferroni post hoc tests 776 
revealed a significant effect of treatment (F(1,1057)=22.45, p<0.0001), injected currents 777 
(F(9,1057)=7.82, p<0.0001) but not significant interaction between the two 778 
(F(9,1057)=0.43, p=0.92). *P < 0.05 as compared to the control. (C) Single action 779 
potentials from A with expanded time scales. TP, threshold potential; RMP, rest 780 
membrane potential. (D) Summary results for the effect of GM-CSF on the threshold 781 
potential, rheobase current and resting membrane potential (unpaired t-test, *p<0.05 782 
as compared to the control). 783 
Figure 3. Effect of GM-CSF on the current amplitude and expression level of 784 
Nav1.7, Nav1.8 and Nav1.9 channels. (A) Relative mRNA expression of Nav1.7, 785 
Nav1.8, Nav1.9, Kv4.2, TMEM16A, P2X3, KCNQ2 and KCNQ3 in cultured DRG 786 
cells after incubation of GM-CSF (200 ng/ml) 24h. (n=9, unpaired t-test, *P < 0.05 as 787 
compared to the control) (B) Relative mRNA expression of Nav1.7, Nav1.8, Nav1.9 788 
in DRG neurons of bone cancer pain at the 7th day. (n=6, unpaired t-test, *P < 0.05 as 789 
compared to the control) (C) Typical current traces and current density-voltage 790 
relationship of total TTX-S, TTX-R, Nav1.8 and Nav1.9 Na+ currents in cultured 791 
DRG cells after incubation with GM-CSF (200 ng/ml) for 24h. (D) Western blot 792 
analysis of expression levels of Nav1.7, Nav1.8 and Nav1.9 proteins in DRG neurons 793 
treated with GM-CSF (200 ng/ml) for 18 h. (n = 3, unpaired t-test, *p<0.05 as 794 
compared to the control).  795 
Figure 4. Down regulation of Nav1.7, Nav1.8 and Nav1.9 reverses nociceptive 796 
behavior evoked by GM-CSF. (A) Application of antisense oligodeoxynucleotides 797 
(ASO) in DRG against Nav1.7, Nav1.8 and Nav1.9 (each ASO, 12.5 Pg/rat, 5Pl) 798 
significantly reduced the mRNA expression level of Nav1.7, Nav1.8 and Nav1.9 799 
increased by GM-CSF treatment, and alleviated mechanical (B) and thermal 800 
hyperalgesia (C) produced by the focal GM-CSF (200 ng) application. For (A) : (n = 801 
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6, unpaired t-test, *P < 0.05 as compared to control; #P < 0.05 with respect to the 802 
corresponding GM-CSF). For (B): two-way ANOVA followed by Bonferroni post 803 
hoc tests revealed a significant effect of treatment (F(3,305)=109.59, p=0) but not time 804 
(F(4,305)=0.78, p=0.54) or interaction between the two (F(12,305)=0.65, p=0.80) for the 805 
left panel. There was a significant effect of treatment (F(3,305)=80.53, p=0), but not 806 
time (F(4,305)=0.20, p=0.94) or interaction between the two (F(12,305)=0.42, p=0.95) for 807 
the middle panel. There was a significant effect of treatment (F(3,335)=109.87, p=0), 808 
but not time F(4,335)=0.89, p=0.47 or interaction between the two (F(12,335)=0.37, 809 
p=0.97) for the right panel. For (C): two-way ANOVA followed by Bonferroni post 810 
hoc tests revealed a significant effect of treatment (F(3,295)=168.25, p=0) and 811 
interaction between treatment and time (F(12,295)=3.73, p<0.0001), but effect of time 812 
was not significant (F(4,295)=1.34, p=0.25) for the left panel. There was a significant 813 
effect of treatment (F(3,295)=336.23, p=0) and an interaction between treatment and 814 
time (F(12,295)=2.04, p=0.02), but effect of time was not significant (F(4,295)=1.05, 815 
p=0.38) for the middle panel. There was a significant effect of treatment 816 
(F(3,250)=274.66, p=0) and interaction between treatment and time (F(12,335)=5.38, 817 
p<0.0001), but effect of time was not significant (F(4,335)=0.71, p=0.74) for the right 818 
panel. *P < 0.05 as compared to the vehicle saline; n=6, #P < 0.05 with respect to the 819 
corresponding GM-CSF). 820 
Figure 5. GM-CSF increase the mRNA expression level of Nav1.7, Nav1.8, 821 
Nav1.9 channel through Jak2-Stat3 signaling pathway. (A) Relative expression of 822 
p-Jak1, p-Jak2, p-Jak3, p-stat3 and p-stat5 in DRG neurons after incubation with 823 
GM-CSF for 25 mins. (n=3, unpaired t-test, *P < 0.05 as compared to control) (B) 824 
Relative mRNA expression level of Nav1.7, Nav1.8, Nav1.9 in DRG neurons 825 
incubated with GM-CSF in the absence or presence of AG-490 (10 PM) and sttatic826 
˄20 PM f˅or 4h. (n=4-6, unpaired t-test, *P < 0.05 as compared to control; #P < 0.05 827 
with respect to the corresponding GM-CSF). (C) Relative Luciferase activity in HEK 828 
293 cells transfected with reporter vector containing Nav1.7, Nav1.8, Nav1.9 829 
promoter regions (pGL3) co-expressed with either pcDNA3.1 (control) or 830 
pcDNA3.1-Stat3 cDNA. (n=3, unpaired t-test, *P < 0.05 as compared to control). D-F. 831 
Relative mRNA level of Nav1.7, Nav1.8, Nav1.9 in ipsilateral DRGs (L5) of rats 832 
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receiving anti-sense oligodeoxynucleotides (ASO) against different Jak and Stat 833 
signaling molecules (12.5 mg/rat, 5 Pl). (n = 6, unpaired t-test, *P < 0.05 as compared 834 
to control; #P < 0.05 with respect to the corresponding GM-CSF). (G-I). Effect of 835 
ASOs against Jak and Stat signaling molecules (12.5 mg/rat, 5 Pl) on hyperalgesia 836 
responses to mechanical and thermal stimuli induced by GM-CSF. ASOs were given 837 
through the DRG cannula for 4 days and then GM-CSF (200ng) was given.  For (G): 838 
two-way ANOVA followed by Bonferroni post hoc tests revealed a significant effect 839 
of treatment (F(3,415)=125.38, p=0) but not time (F(4,415)=0.54, p=0.70) or interaction 840 
between the two (F(12,415)=0.73, p=0.73) for the left panel. There was a significant 841 
effect of treatment (F(3,425)=77.18, p=0) but not time F(4,425)=1.24, p=0.29 or 842 
interaction between the two (F(12,425)=1.65, p=0.07) for the right panel. For (H): 843 
two-way ANOVA followed by Bonferroni post hoc tests revealed a significant effect 844 
of treatment (F(3,415)=110.97, p=0) but not time (F(4,415)=0.38, p=0.82) or interaction 845 
between the two (F(12,415)=0.43, p=0.79) for the left panel. There was a significant 846 
effect of treatment (F(3,440)=115.88, p=0) but not time (F(4,440)=1.40, p=0.25) or 847 
interaction between the two (F(12,440)=1.13, p=0.33) for the right panel. For (I): 848 
two-way ANOVA followed by Bonferroni post hoc tests revealed a significant effect 849 
of treatment (F(3,345)=143.47, p=0) but not time (F(4,415)=0.74, p=0.57) or interaction 850 
between the two (F(12,415)=0.45, p=0.94) for the left panel. There was a significant 851 
effect of treatment (F(3,440)=111.32, p=0) but not time (F(4,440)=0.88, p=0.47) or an 852 
interaction between the two (F(12,440)=0.94, p=0.50) for the right panel. n=6-8.*P < 853 
0.05 as compared to the vehicle saline; #P < 0.05 with respect to the corresponding 854 
GM-CSF). 855 
 856 
 857 
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Table1. Summarized effects of GM-CSF on parameters of action potential  
 Rhobase 
currents(pA) 
 
TP 
(mV) 
 
AP 
amplitude 
(mV) 
 
Depolariz- 
ation rate 
(v/s) 
AHP 
amplitude
˄mV˅ 
AHP 
duration 
(ms) 
 
RMP 
(mV) 
M-type K+ 
current 
(pA/pF) 
Rin 
(M¡) 
 
Control 198.6f9.8 
˄63˅ 
-18.6f0.5 
˄23˅ 
107.9f2.2 
˄19˅ 
 
16.2f0.6 
˄19˅ 
21.3f0.8 
˄23˅ 
 
19.4f0.8 
˄18˅ 
 
55.1f0.9
˄n=43˅ 
 
3.93f1.0 
(9) 
564.0f
51.9 
˄32˅ 
GM-CSF 83.1f2.5** 
˄39˅ 
-20.4f0.6* 
˄22˅ 
113.5f1.8 
˄22˅ 
19.3f0.4* 
˄21˅ 
21.6f0.8 
˄26) 
 
21.6f1.3 
˄18˅ 
55.4f0.9
˄58˅ 
3.54f0.9 
(8) 
504.5f
24.1* 
˄25˅ 
 
Rhobase currents: the depolarized current threshold for evoking the 1st action potential; TP: 
threshold potential; AP: action potential. RMP: resting membrane potential; Rin: input resistance.  
(unpaired t-test,*p<0.05, **p<0.01 compared with the control) 
 
 
